Review Article
Mesenchymal Stem Cells for Cardiac Regeneration: Translation to Bedside Reality
Table 2
MSC clinical trials in MI, chronic ischemia, and heart failure. MI, myocardial infarction; IC, intracoronary infusion; DI, direct intramyocardial injection; IV, intravenous infusion; TESI, transendocardial stem cell injection; EMG; electromechanical guidance; LV, left ventricular; EF, ejection fraction; ESV, end-systolic volume; EDV, end-diastolic volume; , increase; , decrease.
| Group | Condition | Dose (cells) | Followup (months) | Results |
| Chen et al. [104] | Acute MI | | 3 | Myocardial perfusion, LVEF, and LV chamber dimensions | Katritsis et al. [151] | Anteroseptal MI | 2–4 × 106 (IC) | 4 | Wall motion score index and myocardial viability and contractility | Mohyeddin-Bonab et al. [153] | Old MI | (IC)/(DI) | 6–18 | Perfusion defect and LVEF | Osiris therapeutics [146] | Acute MI | (IV) | 6 | Heart function and arrhythmic events | Hare et al. [103] | Acute MI | 0.5, 1.6, and 5 × 106 (IV) | 3 | LVEF and ventricular arrhythmia | Williams et al. [105] | Chronic ischemic cardiomyopathy secondary to MI | 10 repeated injections of 0.5 mL of cell suspension (TESI) | 3–12 | ↓ Cardiac remodeling, ↓ ESV and EDV, and ↑ regional contractility | Bartunek et al. [154] (C-CURE) | Heart failure secondary to ischemic cardiomyopathy | (EMG) | 6 | LVEF and ESV and EDV |
|
|